|
Atomistry » Iron » PDB 5jsh-5kja » 5k7k | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atomistry » Iron » PDB 5jsh-5kja » 5k7k » |
Iron in PDB 5k7k: Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771Enzymatic activity of Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771
All present enzymatic activity of Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771:
1.14.13.80; Protein crystallography data
The structure of Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771, PDB code: 5k7k
was solved by
N.Swain,
J.Chrencik,
with X-Ray Crystallography technique. A brief refinement statistics is given in the table below:
Other elements in 5k7k:
The structure of Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771 also contains other interesting chemical elements:
Iron Binding Sites:
The binding sites of Iron atom in the Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771
(pdb code 5k7k). This binding sites where shown within
5.0 Angstroms radius around Iron atom.
In total only one binding site of Iron was determined in the Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771, PDB code: 5k7k: Iron binding site 1 out of 1 in 5k7kGo back to Iron Binding Sites List in 5k7k
Iron binding site 1 out
of 1 in the Design and Optimization of Biaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7: Discovery of Clinical Candidate Pf-05089771
Mono view Stereo pair view
Reference:
N.A.Swain,
D.Batchelor,
S.Beaudoin,
B.M.Bechle,
P.A.Bradley,
A.D.Brown,
B.Brown,
K.J.Butcher,
R.P.Butt,
M.L.Chapman,
S.Denton,
D.Ellis,
S.R.G.Galan,
S.M.Gaulier,
B.S.Greener,
M.J.De Groot,
M.S.Glossop,
I.K.Gurrell,
J.Hannam,
M.S.Johnson,
Z.Lin,
C.J.Markworth,
B.E.Marron,
D.S.Millan,
S.Nakagawa,
A.Pike,
D.Printzenhoff,
D.J.Rawson,
S.J.Ransley,
S.M.Reister,
K.Sasaki,
R.I.Storer,
P.A.Stupple,
C.W.West.
Discovery of Clinical Candidate 4-[2-(5-Amino-1H-Pyrazol-4-Yl) -4-Chlorophenoxy]-5-Chloro-2-Fluoro-N-1, 3-Thiazol-4-Ylbenzenesulfonamide (Pf-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides As Selective Inhibitors of NAV1.7. J. Med. Chem. V. 60 7029 2017.
Page generated: Tue Aug 6 03:05:32 2024
ISSN: ISSN 1520-4804 PubMed: 28682065 DOI: 10.1021/ACS.JMEDCHEM.7B00598 |
Last articlesZn in 9JPJZn in 9JP7 Zn in 9JPK Zn in 9JPL Zn in 9GN6 Zn in 9GN7 Zn in 9GKU Zn in 9GKW Zn in 9GKX Zn in 9GL0 |
© Copyright 2008-2020 by atomistry.com | ||
Home | Site Map | Copyright | Contact us | Privacy |